In 1925, Merro Pharmaceuticals was founded in Dalian Manchurian Health Research Institute. In 1957, it was the first to develop erythromycin in China and become the earliest antibiotic production base in New China. In 1989, a joint venture with Pfizer Pharmaceuticals of the United States established China Pfizer Pharmaceutical Co., Ltd., the first large-scale joint venture in China. In 2000, the first batch passed the national GMP certification.

In the past 100 years, Merro has never stopped the pace of development. In 2005, it obtained TGA international certification, and in the same year, it exported to New Zealand, which is the first batch of preparation export enterprises in China. In 2014, the solid preparation workshop passed the US FDA certification. In 2015, acquired Polygen Pharmaceutical Factory in the US In 2017, sustained-release preparations were exported to Australia, and multiple ANDA products were approved in the US.

Based on more than 200 products, Merro focuses on the development of slow-release preparations and biological agents, and promotes the extensive cooperation of products and technologies in the international pharmaceutical market, and continuously enhances the company's innovation capabilities to build a factory that meets GMP standards in advanced countries such as Europe and the United States. As the center, we will vigorously develop international and domestic markets and build an international pharmaceutical company that uses technology, service excellence and innovation.